Cardiol Therapeutics Depreciation & Amortization Growth & History (CRDL)

Cardiol Therapeutics's depreciation and amortization was $101,983 for fiscal 2025.

View full Cardiol Therapeutics company overview

Cardiol Therapeutics annual depreciation and amortization history

Cardiol Therapeutics annual depreciation and amortization

Fiscal yearPeriod endedDepreciation and amortizationChangeGrowth
20252025-12-31$101,983−$271,131−72.67%
20242024-12-31$373,114$124,759+50.23%
20232023-12-31$248,355$28,447+12.94%
20222022-12-31$219,908−$513−0.23%
20212021-12-31$220,421−$9,118−3.97%
20202020-12-31$229,539

Cardiol Therapeutics depreciation and amortization trends

Over the last five fiscal years, Cardiol Therapeutics's depreciation and amortization decreased from $229,539 to $101,983, a change of −$127,556. The latest reported quarter, Q2 2026, shows $11,546.

About the metric

What depreciation and amortization mean

Depreciation and amortization allocate the cost of tangible and intangible assets over their useful lives. These non-cash expenses reduce reported earnings and are commonly added back when calculating EBITDA and operating cash flow.

Calculation and source

Reported depreciation and amortization

TickerStat uses a combined depreciation and amortization value when reported. If a company reports the two components separately for an aligned period, they are added together without duplicating overlapping facts. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Cardiol Therapeutics source filings ↗

Community posts

It’s quiet here.

No posts about CRDL yet. Start the conversation.

Write the first post